Company intelligence / Profile preview

BioNexus Gene Lab

Ownership: Public · BGLC
Employees: ~30
Development stage: Commercial

Overview

BioNexus Gene Lab has developed and commercialized a proprietary blood-based genomic screening test that analyzes changes in circulating RNA to predict predisposition to certain cancers, inflammatory diseases, and osteoarthritis. The technology enables non-invasive early detection before symptoms appear. The company also supplies specialty chemical raw materials through its Chemrex subsidiary.

Therapeutic areas: OncologyImmunologyRheumatology
Modalities: RNA-based diagnostics (liquid biopsy)Molecular diagnostic assay
Industry: Molecular Diagnostics

Financials

Market cap: $3.6M
Total revenue: $76.2K
Enterprise value: $254.7K

Beyond the preview

Go deeper on BioNexus Gene Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioNexus Gene Lab.

Explore the full profile